Amatsigroup buys French Pyrofree manufacturing specialist Disposable-Lab

By Dani Bancroft contact

- Last updated on GMT

Amatsigroup buys Pyrofree manufacturing specialist Disposable-Lab

Related tags: Pharmacology

Amatsigroup has acquired single-use processing equipment and packaging tech firm Disposable-Lab SAS as part of a plan to increase its revenue to €50m this year.

According to Amatsigroup the acquisition has expanded its capabilities in injectable drug production, citing D-Lab’s range of processing technologies and proprietary packaging technology, Pyrofree, as examples.

Based in Martillac, D-Lab provides single-use equipment for the production of biological therapies (e.g. immuno-oncology) and “non-conventional processes”, which include products such as sterile powder filling and small batches.

The firm claims it is the first pharmaceutical facility to be specially built for such single use processes, scaling from formulation production to clinical batches down to the microliter scale.

This acquisition fits perfectly with our strategy of being recognized as a leader in the field of sterile clinical batches manufacturing, matching perfectly the pharmaceutical industry increasing needs”​, commented Alain Sainsot, Chairman of Amatsigroup.

disposable_lab_pyrofree_amatsigroup_CDMO_pharmaceutical_martillac
(Image: Disposable-Lab SAS)

Pyrofree

Disposable-Lab’s proprietary Pyrofree technology comprises ready-to-use pyrogen-free packaging vials for aseptic fill and finish of drug candidates.

Pyrogens are endotoxins which can contaminate drug batches and cause fever, with the potential to progress to sepsis and septic shock if they enter the patient’s blood stream.

According to Disposable-Lab the pyrgogen-free vials mean manufacturers do not have to use specialist washing and depyrogenation equipment.

Disposable Lab director Jean Pascal Zambaux, who is also the inventor of the Pyrofree technology, said: “The vials may also be used for commercial safety stocks of injectables,” ​adding that they are “the most cost-effective solution on the market [for] scalability, from small commercial-size batches.”

CDMO expansion

Originally formed from the amalgamation of 4 pharmaceutical firms, since 2014 Amatsigroup has also acquired Belgian SEPS Pharma, Indiana US-based Amatsigroup Inc., Belgian biomanufacturer​, QBiologicals and a French lab nearby in San Augustin, bought from Pierre Fabre.

The firm also previously told Biopharma-Reporter its expansion strategy is focusing on Northern Europe, to include bioclusters across the UK, Switzerland and Germany.

Disposable-Lab reported €2.2 million in revenues last year.

Feature Image: Pyrofree vials (Courtesy of Pall Corp.)

Related news

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Related suppliers

Follow us

Products

View more

Webinars